To cite this paper use one of the standards below:
INTRODUCTION AND OBJECTIVES: Breast cancer (BC) is the most common cancer among women, and the luminal A subtype is the most prevalent. Although this subtype has a favorable prognosis, its response to oxidative stress can be related to resistance to treatment and disease recurrence. Reactive oxygen species (ROS) play a significant role in the development and progression of BC. In high levels, ROS can cause DNA damage, promoting carcinogenesis. In this context, the multifunctional protein APE1 acts to correct DNA damage caused by ROS, and its redox domain regulates the activity of transcription factors, such as NF-κB, which plays a crucial role in modulating oxidative stress through the regulation of anti- and pro-oxidant genes. Therefore, this study aimed to evaluate whether APE1 redox activity could be associated with total ROS in the Luminal A BC subtype. MATERIAL AND METHODS: To confirm that APE1 redox activity was inhibited, NF-κB transcriptional activity was measured via gene reporter assay. Total ROS levels were measured by Flow cytometry with a DCFH-DA probe after treatment with the APE1 redox inhibitor APX2009. The in-silico analyses were performed using the XENA platform with the TCGA-BRCA and TCGA target GTEx samples, using gene signatures of APE1 redox activity, NF-κB activity, and ROS. Patients were grouped into high or low levels of APE1 redox activity and NF-κB activity. RESULTS AND CONCLUSION: Our results showed that NF-κB activity was significantly reduced by 20 μM of APX2009 at 24h. The reduction in total ROS was observed by the same concentration and time, showing that the inhibition of the APE1 redox domain reduces ROS in MCF-7 cells (luminal A BC cells). In silico analysis exhibited a strong positive correlation (r=0.769, p<0.0001) between APE1 redox activity and total ROS in BC patient samples from the TCGA database (BRCA, n=1079). Afterward, in the luminal A subtype, it was observed that in patients with low APE1 activity, total ROS was also significantly reduced (p<0.0001). Considering that APE1 redox regulates NF-κB activity and the correlation between NF-κB and ROS is already well established in the literature, we were willing to find out if the association of APE1 redox and ROS could be through the NF-κB pathway. The results showed that patients with low APE1 redox activity and low NF-κB activity presented significantly reduced total ROS (p<0.0001), suggesting that APE1 redox and ROS association may be due to the NF-κB activity. In conclusion, the inhibition of the APE1 redox domain by APX2009 reduces total ROS levels in luminal A MCF-7 cells. There is a positive association between APE1 redox and ROS in patients with breast cancer, including the luminal A subtype, and this association possibly occurs through the NF-κB pathway. Our findings may open new perspectives for more effective and personalized BC treatments.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper